JMJD2C Inhibitors

JMJD2C (KDM4C) inhibitors primarily function by interfering with the enzyme's histone demethylase activity, which plays a significant role in epigenetic regulation and gene expression. JMJD2C selectively demethylates di- and tri-methylated lysine 9 and lysine 36 on histone H3, thereby influencing chromatin structure and gene transcription. The inhibitors listed, such as GSK-J4 and ML324, directly target the catalytic activity of JMJD2C. These inhibitors are often 2-oxoglutarate analogs or compete with its cofactors, thus blocking the demethylation process. GSK-J4, for instance, is a highly specific inhibitor that directly binds to JMJD2C, impeding its demethylase function. This leads to increased levels of methylated histones, affecting gene expression patterns crucial for various biological processes.

Other inhibitors like IOX1 and Dimethyloxaloylglycine have broader targets, affecting a range of 2-oxoglutarate-dependent dioxygenases, including JMJD2C. This broad specificity can influence multiple pathways simultaneously, offering a wider scope in studying epigenetic regulation. Compounds such as YC-1 and pargyline, although not originally designed as JMJD2C inhibitors, demonstrate activity against this enzyme, showcasing the diverse mechanisms through which JMJD2C activity can be modulated. Natural compounds like Quercetin and Epigallocatechin gallate (EGCG) also exhibit inhibitory effects on JMJD2C, providing insights into the ability of dietary components in influencing epigenetic mechanisms. These inhibitors, with their varied mechanisms of action, underscore the complexity of targeting epigenetic enzymes and the implications of modulating JMJD2C activity.